NCT00498225已完成3 期
Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 834
- 试验地点
- 12
- 主要终点
- Over all survival(OS)
研究概览
简要总结
In patients with unresectable advanced pancreatic cancer, non-inferiority of TS-1 monotherapy and superiority of GEM + TS-1 combination therapy to gemcitabine (GEM) will be verified using survival time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pancreatic carcinoma histologically determined to be adenocarcinoma or adenosquamous carcinoma.
- •Advanced unresectable pancreatic (including pancreatic cancer with local progression and recurrent pancreatic cancer).Presence/absence of measurable lesions is not considered. Patients with measurable lesions must undergo diagnostic imaging tests within 28 days before registration.
- •Patients with no previous treatment (radiotherapy,chemotherapy etc) for pancreatic cancer, except resection. Intra-operative radiotherapy during resection of pancreatic cancer will be permitted, although registration must occur at least 4 weeks after the radiotherapy. Patients that have undergone preoperative/postoperative adjuvant chemotherapy may be enrolled if relapse is diagnosed beyond week 24 after the final administration (on day 169 when the day following the final day is set as day 1).
- •Age: 20 years to 79 years.
- •ECOG Performance Status (PS) of 0 or
- •Sufficient function of major organs as defined below. (The following criteria are satisfied in laboratory tests conducted within 14 days before registration. Laboratory tests conducted 2 weeks before registration (on the same weekday) will be included.) White blood cell count≥ 3500/mm3 Neutrophil count≥ 2000/mm3 Hemoglobin≥9.0 g/dL Platelet count≥100000/mm3 Total bilirubin≤ 2.0 mg/dL* *≤ 3.0 mg/dL in patients treated by biliary drainage for obstructive jaundice. AST and ALT≤ 150 U/L Serum creatinine≤1.2 mg/dL Creatinine clearance≥50mL/min.** **Measured values will be used if available. Otherwise, values calculated by the Cockcroft-Gault method will be used.Formula for estimation:body weight (kg) x [140 - age (years) / 72 x serum creatinine (mg/dL)] *Estimated value will be multiplied by 0.85 for females.
- •Able to take capsules orally.
- •No clinically abnormal ECG findings within 28 days (4 weeks)before registration.
- •Voluntarily signed the written consent form.
排除标准
- •Pulmonary fibrosis or interstitial pneumonia (to be confirmed by chest X-ray within 28 days before enrollment).
- •Watery diarrhoea.
- •Active infections (e.g. patients with pyrexia of 38°C or greater), excluding viral hepatitis.
- •Serious complications (e.g. heart failure, renal failure,hepatic failure, haemorrhagic peptic ulcer, intestinal paralysis, intestinal obstruction or poorly controlled diabetes).
- •Moderate or severe (requiring drainage) ascites or pleural effusion requiring treatment.
- •Metastasis in the CNS.
- •Active double cancer (synchronous double cancer or asynchronous double cancer with disease-free duration of 3 years or less). Carcinoma in situ and lesions of intramucosal carcinoma will not be included in active double cancer and will be permitted for registration.
- •Patients under treatment with flucytosine, phenytoin or warfarin potassium.
- •Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy.
- •Severe mental disorder.
- •Judged ineligible by physicians for participation in the study from a safety viewpoint.
研究组 & 干预措施
1
Experimental
Gemcitabine plus TS-1
干预措施: Gemcitabine plus TS-1 (Drug)
2
Experimental
TS-1
干预措施: TS-1 (Drug)
3
Active Comparator
Gemcitabine
干预措施: Gemcitabine (Drug)
结局指标
主要结局
Over all survival(OS)
时间窗: every course for first three courses, then every other course
次要结局
- progression-free survival (PFS), response rate (RECIST, if measurable), incidence rate of adverse events, incidence rate of adverse drug reactions, QOL (EQ-5D)(adverse events will be collected during treatment)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
3 期
GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract CancerBiliary Tract CancerNCT02182778Kansai Hepatobiliary Oncology Group246
已完成
3 期
Randomized Controlled Trial of Gemcitabine Combined With 125I BrachytherapyLocally Advanced Pancreatic CancerNCT00644618Huazhong University of Science and Technology120
终止
2 期
Phase II Study of Gemcitabine and TS-1 in Biliary Trat CancerBiliary Tract CancerNCT01171755Samsung Medical Center19
已完成
3 期
A Phase III Randomised comparison of Gemcitabine/Carboplatin with Cisplatin/Etoposide in Small Cell Lung Cancerung (small cell) cancerLung (small cell)CancerISRCTN39679215CRI CSG and London Lung Cancer Group (UK)241
Unknown
2 期
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer PatientsCancer of PancreasNCT03278015Chinese PLA General Hospital90